Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack?

Vincent L. Chen

DOI: https://doi.org/10.1111/apt.18123

IF: 9.524

2024-06-27

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Bridi et al papers. To view these articles, visit https://doi.org/10.1111/apt.18099 and https://doi.org/10.1111/apt.18129

pharmacology & pharmacy,gastroenterology & hepatology

What problem does this paper attempt to address?

Editorial: Genetics for noninvasive risk stratification—Finding the needle in the haystack: Authors' reply

Lana Bridi,Veeral Ajmera

DOI: https://doi.org/10.1111/apt.18129

IF: 9.524

2024-06-27

Alimentary Pharmacology & Therapeutics

Abstract:LINKED CONTENT This article is linked to Bridi et al papers. To view these articles, visit https://doi.org/10.1111/apt.18099 and https://doi.org/10.1111/apt.18123

pharmacology & pharmacy,gastroenterology & hepatology
A Non-Parametric Method for Building Predictive Genetic Tests on High-Dimensional Data

Chengyin Ye,Yuehua Cui,Changshuai Wei,Robert C. Elston,Jun Zhu,Qing Lu

DOI: https://doi.org/10.1159/000327299

2011-01-01

Human Heredity

Abstract:Objective: Predictive tests that capitalize on emerging genetic findings hold great promise for enhanced personalized healthcare. With the emergence of a large amount of data from genome-wide association studies (GWAS), interest has shifted towards high-dimensional risk prediction.Methods: To form predictive genetic tests on high-dimensional data, we propose a non-parametric method, called the ‘forward ROC method’. The method adopts a computationally efficient algorithm to search for environment risk factors, genetic predictors on the entire genome, and their possible interactions for an optimal risk prediction model, without relying on prior knowledge of known risk factors. An efficient yet powerful procedure is also incorporated into the method to handle missing data. Results:Through simulations and real data applications, we found our proposed method outperformed the existing approaches. We applied the new method to the Wellcome Trust rheumatoid arthritis GWAS dataset with a total of 460,547 markers. The results from the risk prediction analysis suggested important roles of HLA-DRB1 and PTPN22 in predicting rheumatoid arthritis. Conclusion: We proposed a powerful and robust approach for high-dimensional risk prediction. The new method will facilitate future risk prediction that considers a large number of predictors and their interaction for improved performance.
Nonreplication in Genetic Studies of Complex Diseases—Lessons Learned from Studies of Osteoporosis and Tentative Remedies

Hui Shen,Yongjun Liu,Pengyuan Liu,Robert R Recker,Hong-Wen Deng

DOI: https://doi.org/10.1359/jbmr.041129

IF: 6.39

2005-01-01

Journal of Bone and Mineral Research

Abstract:Abstract Inconsistent results have accumulated in genetic studies of complex diseases/traits over the past decade. Using osteoporosis as an example, we address major potential factors for the nonreplication results and propose some potential remedies. Over the past decade, numerous linkage and association studies have been performed to search for genes predisposing to complex human diseases. However, relatively little success has been achieved, and inconsistent results have accumulated. We argue that those nonreplication results are not unexpected, given the complicated nature of complex diseases and a number of confounding factors. In this article, based on our experience in genetic studies of osteoporosis, we discuss major potential factors for the inconsistent results and propose some potential remedies. We believe that one of the main reasons for this lack of reproducibility is overinterpretation of nominally significant results from studies with insufficient statistical power. We indicate that the power of a study is not only influenced by the sample size, but also by genetic heterogeneity, the extent and degree of linkage disequilibrium (LD) between the markers tested and the causal variants, and the allele frequency differences between them. We also discuss the effects of other confounding factors, including population stratification, phenotype difference, genotype and phenotype quality control, multiple testing, and genuine biological differences. In addition, we note that with low statistical power, even a “replicated” finding is still likely to be a false positive. We believe that with rigorous control of study design and interpretation of different outcomes, inconsistency will be largely reduced, and the chances of successfully revealing genetic components of complex diseases will be greatly improved.
Principles for the post-GWAS functional characterization of cancer risk loci

Matthew L Freedman,Alvaro N A Monteiro,Simon A Gayther,Gerhard A Coetzee,Angela Risch,Christoph Plass,Graham Casey,Mariella De Biasi,Chris Carlson,David Duggan,Michael James,Pengyuan Liu,Jay W Tichelaar,Haris G Vikis,Ming You,Ian G Mills

DOI: https://doi.org/10.1038/ng.840

IF: 30.8

2011-01-01

Nature Genetics

Abstract:Genome wide association studies (GWAS) have identified more than 200 mostly new common low-penetrance susceptibility loci for cancers. The predicted risk associated with each locus is generally modest (with a per-allele odds ratio typically less than 2) and so, presumably, are the functional effects of individual genetic variants conferring disease… Download references
Genetic risk prediction in complex disease

Luke Jostins,Jeffrey C. Barrett

DOI: https://doi.org/10.1093/hmg/ddr378

IF: 5.1214

2011-08-25

Human Molecular Genetics

Abstract:Attempting to classify patients into high or low risk for disease onset or outcomes is one of the cornerstones of epidemiology. For some (but by no means all) diseases, clinically usable risk prediction can be performed using classical risk factors such as body mass index, lipid levels, smoking status, family history and, under certain circumstances, genetics (e.g. BRCA1/2 in breast cancer). The advent of genome-wide association studies (GWAS) has led to the discovery of common risk loci for the majority of common diseases. These discoveries raise the possibility of using these variants for risk prediction in a clinical setting. We discuss the different ways in which the predictive accuracy of these loci can be measured, and survey the predictive accuracy of GWAS variants for 18 common diseases. We show that predictive accuracy from genetic models varies greatly across diseases, but that the range is similar to that of non-genetic risk-prediction models. We discuss what factors drive differences in predictive accuracy, and how much value these predictions add over classical predictive tests. We also review the uses and pitfalls of idealized models of risk prediction. Finally, we look forward towards possible future clinical implementation of genetic risk prediction, and discuss realistic expectations for future utility.

genetics & heredity,biochemistry & molecular biology
A New Paradigm Of Genetic Testing For Hereditary Breast/Ovarian Cancers

Ava Kwong,Jin-Fei Chen,Vivian Y. Shin

DOI: https://doi.org/10.12809/hkmj154634

2016-01-01

Hong Kong Medical Journal

Abstract:Introduction: Genetic risk factors and family history play an important role in breast cancer development. This review aimed to summarise the current genetic testing approach to hereditary breast/ovarian cancer.Methods: A systematic literature review was performed by searching the PubMed database. Publications available online until January 2015 that addressed issues related to hereditary breast/ovarian cancer genetic counselling/testing were selected. The search terms used were "familial breast/ovarian cancer", "susceptibility genes", "genetic counselling", and "genetic testing': The data extracted for this review were analysed by the authors, with a focus on genetic testing for hereditary breast/ovarian cancer.Results: Although a greater proportion of inherited breast/ovarian cancers are due to the BRCA1 and BRCA2 mutations, a number of new genes have emerged as susceptibility candidates, including rare germline mutations in high penetrance genes, such as TP53 and PTEN, and more frequent mutations in moderate/low penetrance genes, such as PALB2, CHEK2 and ATM. Multi-gene testing, if used appropriately, is generally a more cost- and time-effective method than single-gene testing, and may increase the number of patients who can be offered personal surveillance, risk-reduction options, and testing of high-risk family members.Conclusions: Recent advances in molecular genetics testing have identified a number of susceptibility genes related to hereditary breast and/or ovarian cancers other than BRCA1 and BRCA2. The introduction of multi-gene testing for hereditary cancer has revolutionised the clinical management of high-risk patients and their families. Individuals with hereditary breast/ovarian cancer will benefit from genetic counselling/testing.
Editorial: Hereditary colorectal cancer syndromes and risk assessment in the era of precision medicine

Kevin McDonnell,Gad Rennert,Gregory E. Idos

DOI: https://doi.org/10.3389/fonc.2024.1474157

IF: 4.7

2024-10-11

Frontiers in Oncology

Abstract:Dong et al. present a novel approach to preoperative lymph node (LN) metastasis evaluation in rectal cancer. By integrating MRI radiomics with clinical data, they developed a machine learning model that surpasses traditional assessment methods in predicting LN metastasis, achieving a higher positive predictive value. The findings suggest that this approach could significantly aid in tailoring more precise treatment strategies, emphasizing the clinical utility of combining radiomics with conventional clinical data. This research exemplifies how precision medicine can enhance non-invasive diagnostic accuracy and assist in tailoring treatment strategies, thus improving management for patients with colorectal cancer.Building upon this theme of innovative diagnostic techniques, O'Shea et al. introduce an advancement in integrating genomic testing into routine oncology practice. Their study presents a model, derived from comprehensive implementation research, provides a structured approach to improve access to genomic testing for Lynch syndrome. By addressing barriers such as funding, infrastructure, and role delineation, and proposing solutions like embedded genetic counselors and electronic medical record integration, this model aims to streamline genetic testing processes. Its successful implementation could serve as a blueprint for other hereditary cancer syndromes, facilitating broader adoption of precision medicine practices. This study aims to integrate precision medicine into routine oncology practice, ensuring that individuals with hereditary risks receive timely and accurate genetic testing and subsequent personalized care.Complementing these advancements in diagnostics and genetic testing, Brand et al. explore the potential of cytokine profiling to predict colorectal cancer risk in Lynch syndrome patients. By analyzing normal-appearing colorectal tissue, the study identifies immune signatures that distinguish LS patients with a history of CRC from those without. These findings suggest that immune microenvironment profiling could become a valuable tool in CRC risk assessment and prevention strategies, enabling more personalized surveillance and intervention approaches.While Brand et al. focus on risk prediction, another crucial aspect of personalized care for hereditary colorectal cancer syndromes is chemoprevention. In this vein, Mraz et al. provide valuable insights into how chemoprevention is widely discussed and applied, particularly in Lynch syndrome (LS) and familial adenomatous polyposis (FAP). There remains considerable variability in the specifics of these practices. Most professionals recommend aspirin for LS patients, albeit with no consensus on the optimal dosage. This heterogeneity underscores the need for standardized guidelines and further research to optimize chemoprevention strategies, considering individual patient factors to maximize benefits and minimize risks.As the field of chemoprevention continues to evolve, so too does our understanding of genetic risk factors. Highlighting this progression, Li et al. demonstrate the critical role of genetic testing in hereditary cancer syndromes through their identification of a novel splicing variant in the MSH2 gene. This study not only confirms the pathogenicity of the MSH2 c.793-1G>A variant through bioinformatics and functional assays but also underscores the importance of regular surveillance for mutation carriers. Such genetic insights are vital for early detection and prevention of CRC in at-risk populations. By confirming the pathogenicity of this variant, this study supports the role of precision medicine in identifying genetic mutations and highlights the need for regular surveillance and personalized risk assessment for mutation carriers.Moving from genetic risk factors to the broader molecular landscape of colorectal cancer, He et al. offer new perspectives on the molecular underpinnings of colon cancer through their exploration of cuproptosis-related genes. By identifying distinct molecular subtypes associated with different tumor microenvironment characteristics and treatment responses, their research contributes to the development of more tailored therapeutic strategies. This study exemplifies how precision medicine can guide the development of personalized treatment options for patients with hereditary predispositions to colon cancer, further emphasizing the importance of molecular profiling in advancing CRC care.These studies collectively underscore the rapidly evolving landscape of CRC diagnosis and treatment, driven by advancements in genomics, radiomics, and immunology. By presenting these diverse contributions, we aim to provide a comprehensive overview of how precision medicine is reshaping our approach to hereditary CRC syndromes. Looking ahead, it will be crucial to continue validating these findings through large-scale, multicenter studies and to develop standardized -Abstract Truncated-

oncology
Reproductive Carrier Screening: Identifying Families at Risk for Familial Hypercholesterolemia in the United States

Vivienne Souter,Emily Becraft,Samantha Brummit,Bryan Gall,Brittany Prigmore,Yang Wang,Peter Benn

DOI: https://doi.org/10.1161/circgen.123.004457

2024-03-22

Circulation Genomic and Precision Medicine

Abstract:Circulation: Genomic and Precision Medicine, Ahead of Print. BACKGROUND:Familial hypercholesterolemia is a treatable genetic condition but remains underdiagnosed. We reviewed the frequency of pathogenic or likely pathogenic (P/LP) variants in theLDLRgene in female individuals receiving reproductive carrier screening.METHODS:This retrospective observational study included samples from female patients (aged 18–55 years) receiving a 274-gene carrier screening panel from January 2020 to September 2022.LDLRexons and their 10 base pairs flanking regions were sequenced. Carrier frequency for P/LP variants was calculated for the entire population and by race/ethnicity. The most common variants and their likely functional effects were evaluated.RESULTS:A total of 91 637 tests were performed on women identifying as Asian (8.8%), Black (6.1%), Hispanic (8.5%), White (29.0%), multiple or other race/ethnicity (15.0%), and missing (33.0%). Median age was 32.8 years with 83 728 (91%) 1 P/LP variant.LDLRcarrier frequency was higher in Asian (1 in 191 [95% CI, 1 in 142–258]) compared with White (1 in 417 [95% CI, 1 in 326–533];P<0.001) or Black groups (1 in 508 [95% CI, 1 in 284–910];P=0.004). The most common variants differed between populations. Of all variants, at least 25.0% were predicted as null variants.CONCLUSIONS:P/LP variants inLDLRare common. Expanding the use of reproductive carrier screening to include genes associated with FH presents another opportunity to identify people predisposed to cardiovascular disease.

genetics & heredity,cardiac & cardiovascular systems
Abstract IA18: Genetic susceptibility to breast cancer: Recent advances and application to personalised prevention

Douglas F Easton

DOI: https://doi.org/10.1158/1538-7445.advbc23-ia18

IF: 11.2

2024-02-01

Cancer Research

Abstract:Abstract The past two decades have seen dramatic progress in our understanding of the inherited basis of breast cancer, driven by large international collaborative epidemiological studies. Genetic factors identified include rare coding variants in susceptibility genes, and more than 200 common polymorphisms, identified through genome-wide association studies (GWAS) and largely in non-coding regions, that confer more moderate risks. The majority of the common variants are more strongly associated with ER-positive disease, but a subset is specifically associated with ER-negative disease. Variants are strongly enriched for regulatory regions and transcription factor binding sites, and the putative target genes are strongly enriched for known breast cancer drivers: however, the underlying target genes and mechanisms remain largely obscure. The associations for common variants appear to be largely independent of each other and can be summarised by a polygenic risk score (PRS) that is strongly predictive of risk. The most extensively validated PRS, comprising 313 SNPs, is associated with a relative risk of approximately 1.6 per standard deviation; women in the top 1% of the risk distribution have an approximately 4-fold risk of ER-positive disease and 3-fold risk of ER-negative disease. The PRS was developed in women of European ancestry but is also predictive of risk in Asian ancestry women, though less so in African ancestry women. In contrast, despite their widespread use, the evidence for association with cancer for coding variants in genes on genetic testing panels is often weak. Recent very large-scale targeted sequencing studies, however, have clarified the position, providing strong evidence for an association between protein truncating or missense variants and breast cancer risk for nine genes: BRCA1, BRCA2, ATM, CHEK2, PALB2, BARD1, RAD51C, RAD51D and TP53. Recent large-scale exome-wide sequencing analysis has shown that rare variants in several additional genes are also risk associated, with the majority being tumour suppressor genes: these include MAP3K1, ATRIP and SAMHD1. These analyses also demonstrate, however, that the contribution of coding variation, beyond the known genes, is likely to be small. The currently identified variants explain about half of the familial risk of breast cancer. Part of the “missing” heritability is due to weaker common variants, many of which should be identified in ongoing larger GWAS. The causes of the remainder are obscure and may include rare non-coding variants, repeat polymorphisms, and epistatic interactions. Risk discrimination is most powerful when all risk factors are considered. The BOADICEA model, implemented in the CanRisk tool, provides a well validated model that incorporates the effects of gene variants, polygenic risk scores, lifestyle factors and breast density to predict breast and ovarian cancer risk. Multiple translational studies are ongoing to evaluate the feasibility and utility of such personalised risk prediction for stratifying screening and prevention. Citation Format: Douglas F Easton. Genetic susceptibility to breast cancer: Recent advances and application to personalised prevention [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Breast Cancer Research; 2023 Oct 19-22; San Diego, California. Philadelphia (PA): AACR; Cancer Res 2024;84(3 Suppl_1):Abstract nr IA18.

oncology
The genetic family history as a risk assessment tool in internal medicine

Theresa M. Frezzo,Wendy S. Rubinstein,Daniel Dunham,Kelly E. Ormond

DOI: https://doi.org/10.1097/01.gim.0000055197.23822.5e

IF: 8.864

2003-03-01

Genetics in Medicine

Abstract:PURPOSE: The study goals were to (1) determine the proportion of unselected individuals at increased risk for diseases with known genetic components and (2) compare the documentation and quality of risk assessment between a questionnaire, a pedigree interview, and chart review.METHODS: Seventy-eight patients seen in a division of internal medicine were randomized into two groups, which completed a questionnaire or underwent a pedigree interview. Chart notes were compared to both study tools.RESULTS: Sixty-two (79.5%) of the 78 participants scored at increased risk for at least one category. Either of the two study tools found significantly more people at high risk (48/78, 61.5%) than the chart review (31/78, 39.7%) (P = 0.01).CONCLUSIONS: Approximately 20% of patients in an unselected internal medicine practice were at an increased risk that was not documented in reviewed chart notes. Targeted family history analysis reveals patients who require increased medical surveillance, preventive measures, or genetic counseling/testing.

genetics & heredity
Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables

Umberto Vespasiani-Gentilucci,Paolo Gallo,Chiara Dell’Unto,Mara Volpentesta,Raffaele Antonelli-Incalzi,Antonio Picardi

DOI: https://doi.org/10.3748/wjg.v24.i43.4835

IF: 5.374

2018-11-21

World Journal of Gastroenterology

Abstract:Non-alcoholic fatty liver disease (NAFLD) has a prevalence of approximately 30% in western countries, and is emerging as the first cause of liver cirrhosis and hepatocellular carcinoma (HCC). Therefore, risk stratification emerges as fundamental in order to optimize human and economic resources, and genetics displays intrinsic characteristics suitable to fulfill this task. According to the available data, heritability estimates for hepatic fat content range from 20% to 70%, and an almost 80% of shared heritability has been found between hepatic fat content and fibrosis. The rs738409 single nucleotide polymorphism (SNP) in patatin-like phospholipase domain-containing protein 3 gene and the rs58542926 SNP in transmembrane 6 superfamily member 2 gene have been robustly associated with NAFLD and with its progression, but promising results have been obtained with many other SNPs. Moreover, there has been proof of the additive role of the different SNPs in determining liver damage, and there have been preliminary experiences in which risk scores created through a few genetic variants, alone or in combination with clinical variables, were associated with a strongly potentiated risk of NAFLD, non-alcoholic steatohepatitis (NASH), NASH fibrosis or NAFLD-HCC. However, to date, clinical translation of genetics in the field of NAFLD has been poor or absent. Fortunately, the research we have done seems to have placed us on the right path: We should rely on longitudinal rather than on cross-sectional studies; we should focus on relevant outcomes rather than on simple liver fat accumulation; and we should put together the genetic and clinical information. The hope is that combined genetic/clinical scores, derived from longitudinal studies and built on a few strong genetic variants and relevant clinical variables, will reach a significant predictive power, such as to have clinical utility for risk stratification at the single patient level and even to esteem the impact of intervention on the risk of disease-related outcomes. Well-structured future studies would demonstrate if this vision can become a reality.

gastroenterology & hepatology
Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification

Peh Joo Ho,Weang Kee Ho,Alexis J. Khng,Yen Shing Yeoh,Benita Kiat-Tee Tan,Ern Yu Tan,Geok Hoon Lim,Su-Ming Tan,Veronique Kiak Mien Tan,Cheng-Har Yip,Nur-Aishah Mohd-Taib,Fuh Yong Wong,Elaine Hsuen Lim,Joanne Ngeow,Wen Yee Chay,Lester Chee Hao Leong,Wei Sean Yong,Chin Mui Seah,Siau Wei Tang,Celene Wei Qi Ng,Zhiyan Yan,Jung Ah Lee,Kartini Rahmat,Tania Islam,Tiara Hassan,Mei-Chee Tai,Chiea Chuen Khor,Jian-Min Yuan,Woon-Puay Koh,Xueling Sim,Alison M. Dunning,Manjeet K. Bolla,Antonis C. Antoniou,Soo-Hwang Teo,Jingmei Li,Mikael Hartman,Lester Chee Hao Leong…

DOI: https://doi.org/10.1186/s12916-022-02334-z

IF: 9.3

2022-04-27

BMC Medicine

Abstract:Family history, and genetic and non-genetic risk factors can stratify women according to their individual risk of developing breast cancer. The extent of overlap between these risk predictors is not clear.

medicine, general & internal
Editorial: Integrative analysis for complex disease biomarker discovery.

Hai-Hui Huang,Jie Li,William C Cho

DOI: https://doi.org/10.3389/fbioe.2023.1273084

IF: 5.7

2023-01-01

Frontiers in Bioengineering and Biotechnology

Abstract:EDITORIAL article Front. Bioeng. Biotechnol., 21 August 2023Sec. Preclinical Cell and Gene Therapy Volume 11 - 2023 | https://doi.org/10.3389/fbioe.2023.1273084
Abstract 16592: A Next-Generation Artificial Intelligence-Based Integrated Genetic-Epigenetic Prediction of 5-Year Risk for Coronary Heart Disease

Meeshanthini V Dogan,Ronald L Simons,Steven Beach,Amaury Lendasse,Robert A Philibert

DOI: https://doi.org/10.1161/circ.138.suppl_1.16592

IF: 37.8

2018-11-06

Circulation

Abstract:Coronary heart disease (CHD) is a leading cause of death in the US. CHD associated morbidity and mortality can be reduced if those at risk can be identified well in advance, to put in place prevention interventions prior to an acute coronary event. Limitations of current approaches call for additional efforts to improve risk predictions. We recently developed a Precision Medicine tool capable of predicting 5-year risk, that can also guide personalized prevention interventions and monitor changes in risk over time. It was developed using an application of AI, machine learning, in the Framingham Heart Study to mine integrated genetic-epigenetic biosignatures that capture the complex interplay between our genome and the environment in conferring risk for CHD. The training and test sets consisted of 1180 (19/695 females and 23/485 males developed symptomatic CHD within 5-years) and 524 (8/293 females and 12/231 males developed symptomatic CHD within 5-years) individuals, respectively, of Northern European ancestry. Non-linear data mining and modeling techniques were employed on the training set to identify prediction signatures from genome-wide SNP and DNA methylation (DNAm) data. We identified 14 DNAm and 10 SNPs from the training set (training bootstrap average sensitivity and specificity of 0.61 and 0.71, respectively) that predicted the 5-year risk in the test set with a sensitivity and specificity of 0.60 and 0.69, respectively. Performance was compared to that of the Framingham Risk Score (FRS) and the ASCVD Risk Estimator. The sensitivity and specificity in the test set were 0.05 and 0.99 for FRS, and 0.38 and 0.85 for ASCVD. Even with a small number of incident cases, our tool performed with superior sensitivity, which is vital because, while a false positive would result in additional testing, a false negative can be detrimental. Unlike genetics, because DNAm is dynamic, it can be mapped to actionable risk factors to guide personalized interventions and over time, re-assess risk and continuously monitor heart health. We demonstrate translational feasibility of this tool via next-gen digital PCR assays. Additional efforts are ongoing to optimize, validate and extend our tool to further improve performance in larger, more ethnically diverse cohorts.

cardiac & cardiovascular systems,peripheral vascular disease
A New Frontier for Cancer Genetics: Identification of Germline-Somatic Associations

Siddhartha P Kar

DOI: https://doi.org/10.1158/0008-5472.CAN-23-0152

2023-04-14

Abstract:Studies of the inherited or germline genome have identified rare mutations with large effects and common polymorphisms of more modest effect sizes that are associated with cancer risk. This research has substantially illuminated the etiology and development of cancer, with particular relevance to cancer prevention. In parallel, studies of the somatic or tumor genome have been instrumental in identifying the key drivers of cancer progression, significantly informing modern cancer therapy. While these studies have thus far largely been performed separately, integrative studies where the germline and somatic genomes are mapped in the same individuals have the potential to yield novel and holistic insights into cancer biology. In this issue of Cancer Research, Liu and colleagues report the results of integrative germline-somatic analyses in over 12,000 patients with cancer and 11 cancer types, identifying several associations where inherited variants that regulate the expression of a nearby gene in normal tissues are associated with tumor mutations in the same gene or with genome-wide somatic traits such as the tumor mutational burden. Although considerable follow-up work is required, the study is an important contribution to an emerging body of evidence that is demonstrating that the germline has a vital role in shaping the tumor genome. See related article by Liu et al., p. 1191.
Exploring the genetic and epigenetic underpinnings of early-onset cancers: Variant prioritization for long read whole genome sequencing from family cancer pedigrees

Melissa Kramer,Sara Goodwin,Robert Wappel,Matilde Borio,Kenneth Offit,Darren R Feldman,Zsofia K Stadler,W. Richard McCombie

DOI: https://doi.org/10.1101/2024.06.27.601096

2024-07-02

Abstract:Despite significant advances in our understanding of genetic cancer susceptibility, known inherited cancer predisposition syndromes explain at most 20% of early-onset cancers. As early-onset cancer prevalence continues to increase, the need to assess previously inaccessible areas of the human genome, harnessing a trio or quad family-based architecture for variant filtration, may reveal further insights into cancer susceptibility. To assess a broader spectrum of variation than can be ascertained by multi-gene panel sequencing, or even whole genome sequencing with short reads, we employed long read whole genome sequencing using an Oxford Nanopore Technology (ONT) PromethION of 3 families containing an early-onset cancer proband using a trio or quad family architecture. Analysis included 2 early-onset colorectal cancer family trios and one quad consisting of two siblings with testicular cancer, all with unaffected parents. Structural variants (SVs), epigenetic profiles and single nucleotide variants (SNVs) were determined for each individual, and a filtering strategy was employed to refine and prioritize candidate variants based on the family architecture. The family architecture enabled us to focus on inapposite variants while filtering variants shared with the unaffected parents, significantly decreasing background variation that can hamper identification of potentially disease causing differences. Candidate de novo and compound heterozygous variants were identified in this way. Gene expression, in matched neoplastic and pre-neoplastic lesions, was assessed for one trio. Our study demonstrates the feasibility of a streamlined analysis of genomic variants from long read ONT whole genome sequencing and a way to prioritize key variants for further evaluation of pathogenicity, while revealing what may be missing from panel based analyses.

Genomics
Needles in the Haystack: Identifying Individuals Present in Pooled Genomic Data

Rosemary Braun,William Rowe,Carl Schaefer,Jinghui Zhang,Kenneth Buetow

DOI: https://doi.org/10.1371/journal.pgen.1000668

2009-05-21

Abstract:Recent publications have described and applied a novel metric that quantifies the genetic distance of an individual with respect to two population samples, and have suggested that the metric makes it possible to infer the presence of an individual of known genotype in a sample for which only the marginal allele frequencies are known. However, the assumptions, limitations, and utility of this metric remained incompletely characterized. Here we present an exploration of the strengths and limitations of that method. In addition to analytical investigations of the underlying assumptions, we use both real and simulated genotypes to test empirically the method's accuracy. The results reveal that, when used as a means by which to identify individuals as members of a population sample, the specificity is low in several circumstances. We find that the misclassifications stem from violations of assumptions that are crucial to the technique yet hard to control in practice, and we explore the feasibility of several methods to improve the sensitivity. Additionally, we find that the specificity may still be lower than expected even in ideal circumstances. However, despite the metric's inadequacies for identifying the presence of an individual in a sample, our results suggest potential avenues for future research on tuning this method to problems of ancestry inference or disease prediction. By revealing both the strengths and limitations of the proposed method, we hope to elucidate situations in which this distance metric may be used in an appropriate manner. We also discuss the implications of our findings in forensics applications and in the protection of GWAS participant privacy.

Genomics,Quantitative Methods,Applications,Computation
Editorial: Emerging talents in human and medical genomics

Vanessa Meyer,Stephen J. Bush,Angela Botes,Mandeep Kaur

DOI: https://doi.org/10.3389/fgene.2024.1497486

IF: 3.7

2024-10-08

Frontiers in Genetics

Abstract:The field of human genomics has progressed extensively since the publication of the first draft of the human genome in 2001. A simple search in PubMed using the keywords 'Human Genomics' produced a list of 5 521 articles published between the years 1990-2000, 15 740 in the first decade of the 21 st century (2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010), 57 346 in the years 2011-2020, and from 2021 until 24 th August 2024, 32 856 articles have been published. Genomics has evidently found its application in a variety of research areas, diversifying our knowledge and understanding of the biological mechanisms of health and disease. This broad topic provided a platform specifically to earlycareer researchers (the first or co-first authors were all either enrolled on under-or postgraduate programmes) to publish their work in the fields of human and medical genomics and enable them to experience the collaborative aspects of the publishing process and workflows. The topic highlights studies that have made innovative use of genomics technologies to address issues related to maternal health, surgical treatment, and hearing loss.Lin et al. characterized the extrachromosomal circular DNA (eccDNA) from placental trophoblasts in placental and maternal plasma in a small number of samples to provide a proof-of-concept to use eccDNA as a biomarker for foetal growth restriction (FGR), a perinatal complication in foetuses. The authors performed eccDNA sequencing on a small number of samples and the analysis revealed the enrichment of both multi-chromosomal-fragment and single-fragment eccDNA in placenta, while only single-fragment eccDNA was identified in maternal plasma. The comparison of data from plasma between FGR and control groups led to the identification of abundant genes such as IGF2 and ZNF445 in the FGR group (linked to epigenetic regulation of gene expression and genomic imprinting), whereas ARG1, CCND1, CYP1A1, EZR, GPR68, MYO1C, and XPO4 (linked to response to vitamins, response to nutrient levels, and positive regulation of protein transport) were found to be abundant genes in the control group. Additionally, placental eccDNA-associated genes, those which were associated with immunity-related gene ontology terms, showed differential abundance between the FGR and control groups. This integrated data analysis from both placental and maternal plasma, combined with genomic annotation, offered insights into the potential of using eccDNA as biomarker of FGR and opens doors for using maternal plasma eccDNA signatures for future investigations into pregnancy-related diseases and complications.Qi et al. sheds light on a critical intersection of virology and reproductive health. This research is particularly timely given the ongoing global impact of COVID-19 and its far-reaching implications. The study examines the expression of SARS-CoV-2associated molecules in the endometrium, revealing significant insights into how these factors vary throughout the menstrual cycle. One of the most compelling aspects of this study is its focus on women with recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF). The significant reduction in TMPRSS2 (transmembrane protease serine 2) expression in the RIF group compared to the controls underscores the need for further investigation into how SARS-CoV-2 might exacerbate reproductive challenges. Similarly, in women with RPL, the peak expression of the host cell receptor basigin (BSG) during the window of implantation suggests a potential period of heightened vulnerability to SARS-CoV-2. Despite the limited sample numbers, this study is a crucial step toward understanding the interplay between viral infections and reproductive health and helps address the unique challenges faced by women with reproductive health issues.Fernández-Boyano et al. innovatively applied bioinformatics and artificial intelligence to design a model (eoPred) that can be used to identify early-onset preeclampsia from DNA methylation data and predict placental phenotype regardless of cell composition. Preeclampsia is a life-threatening condition and the leading cause of maternal and infant illness and death in the US. The package, which is available at https://www.bioconductor.org/packages/release/bioc/html/planet.html, is expected to significantly enhance current approaches at identifying placental insufficiency and be useful in larger, more complex EWAS studies as well.Turning from its use in maternal health, Kueng et al. shifts our focus to the practical use of genomics as a non-invasive tool to monitor allograft injury after solid organ transplants. The authors compared three methods currently used to quantify donor derived cell-free DNA (dd-cfDNA) and assessed the strengths and limitations of each. While the relative quantification of dd-cfDNA yielded comparable results between techniques, the absolute quantification methods showed mo -Abstract Truncated-

genetics & heredity
Identifying somatic fingerprints of cancers defined by germline and environmental risk factors

Saptarshi Chakraborty,Zoe Guan,Caroline E. Kostrzewa,Ronglai Shen,Colin B. Begg

DOI: https://doi.org/10.1002/gepi.22565

2024-05-02

Genetic Epidemiology

Abstract:Numerous studies over the past generation have identified germline variants that increase specific cancer risks. Simultaneously, a revolution in sequencing technology has permitted high‐throughput annotations of somatic genomes characterizing individual tumors. However, examining the relationship between germline variants and somatic alteration patterns is hugely challenged by the large numbers of variants in a typical tumor, the rarity of most individual variants, and the heterogeneity of tumor somatic fingerprints. In this article, we propose statistical methodology that frames the investigation of germline‐somatic relationships in an interpretable manner. The method uses meta‐features embodying biological contexts of individual somatic alterations to implicitly group rare mutations. Our team has used this technique previously through a multilevel regression model to diagnose with high accuracy tumor site of origin. Herein, we further leverage topic models from computational linguistics to achieve interpretable lower‐dimensional embeddings of the meta‐features. We demonstrate how the method can identify distinctive somatic profiles linked to specific germline variants or environmental risk factors. We illustrate the method using The Cancer Genome Atlas whole‐exome sequencing data to characterize somatic tumor fingerprints in breast cancer patients with germline BRCA1/2 mutations and in head and neck cancer patients exposed to human papillomavirus.

genetics & heredity,mathematical & computational biology
Genetic Insights through Chinese VTE Pedigree Interpretation Using the ACMG Method: Unraveling Potencial Genetic Risk Factors

Zhang,Z.,Wan,Z.,Su,M.,Li,H.,Zhai,Z.

DOI: https://doi.org/10.1183/13993003.congress-2024.oa5557

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Aim: The study aims to bridge existing gaps in understanding VTE genetics by focusing on familial units with unexplained VTE occurrences. Methodology: Participant Selection: Identify and recruit individuals from 9 Chinese pedigrees with a clear family history of VTE. Employ high-throughput whole-genome sequencing (WGS) technology for comprehensive genetic analysis. Utilize the American College of Medical Genetics and Genomics (ACMG) scoring system for variant interpretation and familial analysis. Result: We successfully identified and interpreted 10 variants directly linked to thrombosis through harmful mutation filtering and VTE-specific ACMG rating, which enabled the interpretation of thrombotic risk in 8 pedigree, shedding light on the elusive genetic underpinnings of VTE within these cohorts. Moreover, our investigation revealed notable risk mutations within the ADAMTSs gene family associated with thrombosis susceptibility across multiple families, completing the interpretation of all pedigrees. Conclusion: By applying the ACMG scoring system and evidence-based medicine principles, the study seeks to identify and characterize potential genetic factors associated with VTE, ultimately providing valuable insights for clinical practice and future research in VTE genetics.

respiratory system

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack?

Editorial: Genetics for noninvasive risk stratification—Finding the needle in the haystack: Authors' reply

A Non-Parametric Method for Building Predictive Genetic Tests on High-Dimensional Data

Nonreplication in Genetic Studies of Complex Diseases—Lessons Learned from Studies of Osteoporosis and Tentative Remedies

Principles for the post-GWAS functional characterization of cancer risk loci

Genetic risk prediction in complex disease

A New Paradigm Of Genetic Testing For Hereditary Breast/Ovarian Cancers

Editorial: Hereditary colorectal cancer syndromes and risk assessment in the era of precision medicine

Reproductive Carrier Screening: Identifying Families at Risk for Familial Hypercholesterolemia in the United States

Abstract IA18: Genetic susceptibility to breast cancer: Recent advances and application to personalised prevention

The genetic family history as a risk assessment tool in internal medicine

Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables

Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification

Editorial: Integrative analysis for complex disease biomarker discovery.

Abstract 16592: A Next-Generation Artificial Intelligence-Based Integrated Genetic-Epigenetic Prediction of 5-Year Risk for Coronary Heart Disease

A New Frontier for Cancer Genetics: Identification of Germline-Somatic Associations

Exploring the genetic and epigenetic underpinnings of early-onset cancers: Variant prioritization for long read whole genome sequencing from family cancer pedigrees

Needles in the Haystack: Identifying Individuals Present in Pooled Genomic Data

Editorial: Emerging talents in human and medical genomics

Identifying somatic fingerprints of cancers defined by germline and environmental risk factors

Genetic Insights through Chinese VTE Pedigree Interpretation Using the ACMG Method: Unraveling Potencial Genetic Risk Factors